A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery (HEP-SC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective and endpoints of the study is compare the efficacy of two products containing heparin sodium, evaluating if the formulation produced by Eurofarma can be considered non-inferior to the reference product.
| Condition | Intervention | Phase |
|---|---|---|
|
Hip Fracture Surgery |
Biological: Heparin Sodium - Eurofarma Biological: Heparin Sodium - APP Pharmaceuticals |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Phase III, Non-inferiority, Randomized, Double-blind Trial Comparing Eurofarma Unfractionated Sodium Heparin 5,000 IU to APP Pharmaceuticals Unfractionated Sodium Heparin 5,000 IU in the Thromboprophylaxis of Geriatric Patients Who Underwent Hip Fracture Surgery. |
- The Primary endpoint will be frequency of deep venous thrombosis (DVT) determined by Doppler ultrasound (DUS). [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
- The Secundary endpoint will be proximal and distal DVT [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 544 |
| Study Start Date: | October 2011 |
| Study Completion Date: | October 2012 |
| Primary Completion Date: | October 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Heparin Sodium - Eurofarma |
Biological: Heparin Sodium - Eurofarma
Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
|
| Active Comparator: Heparin Sodium - APP Pharmaceuticals |
Biological: Heparin Sodium - APP Pharmaceuticals
Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
|
Detailed Description:
The primary objective of the study is to assess the efficacy of unfractionated heparin sodium of porcine origin (Eurofarma) in the prophylaxis of VTE relative to unfractionated heparin sodium of porcine origin from APP Pharmaceuticals. The primary endpoint will be the frequency of DVT determined by Doppler ultrasound (DUS).
Eligibility| Ages Eligible for Study: | 60 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
In order to be enrolled in this study, eligible patients must meet all criteria below:
- ICF signing;
- Aged 60 to 85 years old;
- Indication of hip orthopedic surgery due to fracture occurred within the last 5 days;
- Normal coagulation profile or with alterations up to 25% of normal values.
Exclusion Criteria:
Patients who meet any of the following criteria will not be eligible for the study:
- Previous hip surgery;
- Fracture secondary to the presence of metastasis;
- Recent traumatic brain, thoracic, or abdominal injury (up to 30 days before study start);
- Recent occurrence (up to 30 days before study start) of cerebrovascular accident;
- Serum concentration of hemoglobin below 9 g/dL;
- Prior occurrence (in the last 5 years) of confirmed or suspected thromboembolic event;
- Occurrence of major bleeding in the last 6 months (any spontaneous gastrointestinal bleeding; central nervous system bleeding; massive epistaxis, or gum bleeding; gross hematuria, or vaginal bleeding);
- Confirmed or suspected blood dyscrasia;
- Diagnosis of neoplasm other than in situ in the last 24 months or any active neoplasm (neoplasms in situ do not prevent patient from participating);
- Liver or kidney failure;
- Clinically significant gastrointestinal cardiovascular, neurological disease, or laboratory abnormalities, which at the investigator's opinion, may interfere with individual's participation in the study or with assessment of individual's response to treatment;
- Hypersensitivity to heparin;
- Previous use (15 days before study start) of oral anticoagulants or expected use during the study (see Appendix B);
- Recent participation (previous 12 months) in a clinical trial.
Contacts and Locations| Brazil | |
| Santa Casa de Misericórdia de Belo Horizonte | |
| Belo Horizonte, Minas Gerais, Brazil, 30150221 | |
| Centro de Pesquisa Clínica da Santa Casa de Misericórida de Juíz de Fora | |
| Juiz de Fora, Minas Gerais, Brazil, 36021-630 | |
| Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul | |
| Porto Alegre, Rio Grande do Sul, Brazil, 90610-000 | |
| Associação Hospitalar Moinhos de Vento | |
| Porto Alegre, Rio Grande do Sul, Brazil, 90035-001 | |
| Irmandade Santa Casa de Misericórdia de Marília | |
| Marília, São Paulo, Brazil, 17515-900 | |
More Information
No publications provided
| Responsible Party: | Eurofarma Laboratorios S.A. |
| ClinicalTrials.gov Identifier: | NCT01352039 History of Changes |
| Other Study ID Numbers: | EF098 - HEP-SC |
| Study First Received: | May 10, 2011 |
| Last Updated: | October 15, 2012 |
| Health Authority: | Brazil: National Health Surveillance Agency |
Keywords provided by Eurofarma Laboratorios S.A.:
|
Heparin Sodium Thromboprophylaxis Hip Fracture Surgery. |
Additional relevant MeSH terms:
|
Fractures, Bone Hip Fractures Wounds and Injuries Femoral Fractures Hip Injuries Leg Injuries Calcium heparin Heparin |
Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 16, 2013